|
Conference/Events
|
ARVO 2022 to be held in… ARVO 2022 to be held in Denver, CO on May 1-4. ShowHide Related Items >><< - 04/28/22
- Allogene Therapeutics appoints Lundeen as Chief People Officer
- 04/19/22
- Unity Biotechnology doses first patient in ENVISION study of UBX1325
- 04/12/22
- Unity Biotechnology completes enrollment in BEHOLD study
- 03/15/22
- Unity Biotechnology expects cash to fund operations into 1Q23
- 05/02/22
- Stoke Therapeutics presents new in-vivo data for STK-002
- 12/03/21
- Stoke Therapeutics presents data from Phase 1/2a MONARCH study of STK-001
- 04/29/22
- Genentech announces new three-year data from FIREFISH study
- 04/25/22
- Roche sees FY22 sales stable or up in low single digits
- 04/25/22
- Roche confirms outlook for 2022
- 04/22/22
- Roche reports CHMP recommends approval of Tecentriq as adjuvant NSCLC treatment
- 02/09/22
- Regenxbio reporting 'additional positive interim data' from MPS II trial
- 01/06/22
- Regenxbio announces FDA clearance of IND for clinical trial of RGX-202
- 11/22/21
- Regenxbio announces FDA Orphan Drug Designation for RGX-202
- 11/12/21
- Regenxbio reports additional positive interim data from trials of RGX-314
- 04/19/22
- Regeneron to acquire Checkmate Pharmaceuticals for $10.50 per share in cash
- 04/19/22
- Regeneron to acquire Checkmate Pharmaceuticals for $10.50 per share in cash
- 04/19/22
- Regeneron to acquire Checkmate Pharmaceuticals for $10.50 per share in cash
- 04/19/22
- Regeneron to acquire Checkmate Pharmaceuticals for $10.50 per share in cash
- 04/13/22
- ProQR Therapeutics announces additional sepofarsen Illuminate trial analyses
- 04/13/22
- ProQR Therapeutics expects cash to fund operations into 2025
- 04/13/22
- ProQR Therapeutics to reduce workforce by 30%, CSO Naveed Shams to depart
- 04/13/22
- ProQR Therapeutics suspends development of QR-1123, QR-504a
LCTX Lineage Cell Therapeutics - 04/25/22
- Lineage Cell Therapeutics announces new cell therapy development program
- 04/20/22
- Enochian Biosciences appoints Binette as EVP for Research, Development
- 04/13/22
- Lineage Cell announces Cancer Research UK completes enrollment for VAC2 trial
- 12/20/21
- Lineage Cell Therapeutics enters license agreement with Roche, Genentech
- 02/23/22
- Kodiak Sciences announces KSI-301 trial did not meet primary efficacy endpoint
- 02/03/22
- Kodiak Sciences completes enrollment in GLEAM, GLIMMER trials
- 12/16/21
- Kodiak Sciences completes enrollment in BEACON trial
KALA Kala Pharmaceuticals - 05/03/22
- Kala announces new commercial, Medicare coverage for EYSUVIS
- 05/01/22
- Kala Pharmaceuticals to present clinical data for KPI-012 at ARVO Annual Meeting
- 03/29/22
- Kala Pharmaceuticals expects cash to fund operations into Q2 of 2023
- 03/08/22
- Kala Pharmaceuticals announces EYSUVIS now covered by UnitedHealthcare, Cigna
- 05/02/22
- FDA announces tentative advisory committee meetings on COVID-19 vaccines
- 05/02/22
- Roivant Sciences announces collaborations in targeted protein degradation
- 04/19/22
- Johnson & Johnson announces $77M opioid settlement with Alabama
- 04/19/22
- Johnson & Johnson says continues to invest in R&D at 'competitive levels'
HZNP Horizon Therapeutics - 05/03/22
- Horizon Therapeutics announces dazodalibep trial meets primary endpoint
- 05/02/22
- Roivant Sciences appoints Srini Ramanathan as CDO
- 05/02/22
- Horizon Therapeutics announces EC approval of Uplinza
- 04/11/22
- Eton Pharmaceuticals CFO Wilson Troutman to retire, James Gruber to succeed
- 04/26/22
- Editas Medicine receives FDA Rare Pediatric Disease designation for EDIT-301
- 04/14/22
- Editas Medicine appoints Gilmore O'Neill as CEO
- 04/11/22
- Editas Medicine announces dosing of first pediatric patient in BRILLIANCE trial
- 04/08/22
- Editas Medicine reports engineered iNK cell preclinical data
- 04/26/22
- Cathie Wood's ARK Investment bought 1.3M shares of Ginkgo Bioworks today
- 04/25/22
- Cathie Wood's ARK Investment bought 232.6K shares of Ginkgo Bioworks today
- 04/20/22
- Cathie Wood's ARK Investment bought 881K shares of Ginkgo Bioworks today
- 02/15/22
- FDA grants Celularity fast track designation for CYNK-101
- 02/14/22
- Celularity's treatment of gastric junction cancer gets FDA orphan designation
- 01/18/22
- Celularity receives Fast Track Designation for CYNK-101
- 12/27/21
- Celularity receives Fast Track Designation for CYNK-001
- 03/31/22
- Celanese sees EPS accretion from KEP restructuring 15-20c over three years
- 02/18/22
- DuPont to divest majority of mobility and materials segment to Celanese for $11B
- 02/18/22
- Celanese to acquire majority of DuPont M&M business for $11B in cash
- 02/07/22
- Linde expands existing agreement with Celanese
- 03/17/22
- BioMarin's hemophilia A candidate shows efficacy in published article
- 02/24/22
- BioMarin trading resumes
- 02/24/22
- BioMarin trading halted, volatility trading pause
- 02/17/22
- BioMarin provides updates on progress in gene therapy programs
- 04/22/22
- Ginkgo Bioworks announces partnership with Bayer
- 04/12/22
- ALX Oncology appoints Canamasas to board of directors
- 04/11/22
- 22nd Century appoints Calvin Treat as CSO
- 03/24/22
- Bayer's Monsanto settles with Ohio Attorney General for $80M
- 03/22/22
- Applied Genetic announces pricing of public offering of common stock
- 02/14/22
- Applied Genetic expects cash to fund operations into 2023
- 02/08/22
- Applied Genetic announces interim data from studies of AGTC-401, AGTC-402
- 01/11/22
- Applied Genetic exceeds enrollment target in SKYLINE trial of AGTC-501
AERI Aerie Pharmaceuticals - 03/21/22
- Ocugen names Jessica Crespo as Chief Accounting Officer
- 03/18/22
- Aerie Pharmaceuticals announces Peter Lang as CFO
- 02/24/22
- Aerie Pharmaceuticals sees FY Glaucoma franchise net product revenues up 16%-25%
- 02/24/22
- Aerie Pharmaceuticals names Gary Sternberg as Chief Medical Officer
ADVM Adverum Biotechnologies - 05/01/22
- Adverum presents additional efficacy, safety data from OPTIC trial of ADVM-022
- 04/06/22
- Adverum proceeds with IND amendment for wet AMD trial after FDA Type C feedback
- 03/29/22
- Nkarta Adverum appoints Thedinga to board of directors
- 02/07/22
- Adverum Biotechnologies appoints Richard Beckman as CMO
- 04/29/22
- Abeona Therapeutics announces pricing of $25M private placement
- 03/14/22
- Abeona Therapeutics reaches target enrollment in Phase 3 VIITAL study of EB-101
- 03/09/22
- Abeona Therapeutics CFO Edward Carr resigns
- 12/22/21
- Abeona issues letter to shareholders on 2022 anticipated milestones
- 04/29/22
- AbbVie's RINVOQ approved by FDA for treatment of active AS
- 04/29/22
- AbbVie says no plans to cut R&D investments in 2023
- 04/29/22
- AbbVie says cystic fibrosis combination drug missed study goal
- 04/29/22
- AbbVie says confident in long-term fundamentals of business
- 05/03/22 Morgan Stanley
- Vertex upgraded to Equal Weight at Morgan Stanley following AbbVie failure
- 05/02/22 Morgan Stanley
- AbbVie's recent weakness a buying opportunity, says Morgan Stanley
- 05/02/22 Wells Fargo
- AbbVie price target raised to $200 from $165 at Wells Fargo
- 05/02/22 Cowen
- Genmab initiated with a Market Perform at Cowen
- 11/30/21 SVB Leerink
- Abeona Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
- 11/29/21 H.C. Wainwright
- Abeona Therapeutics price target lowered to $4 from $5 at H.C. Wainwright
- 07/19/21 H.C. Wainwright
- Abeona Therapeutics price target lowered to $5 from $8 at H.C. Wainwright
ADVM Adverum Biotechnologies - 03/29/22 Chardan
- Adverum Biotechnologies transferred with Neutral at Chardan
- 07/23/21
- Fly Intel: Top five analyst downgrades
- 07/23/21 Goldman Sachs
- Adverum Biotechnologies downgraded to Neutral from Buy at Goldman Sachs
- 07/23/21 SVB Leerink
- Adverum Biotechnologies price target lowered to $2 from $5
AERI Aerie Pharmaceuticals - 02/28/22 Citi
- Aerie Pharmaceuticals price target lowered to $13 from $23 at Citi
- 02/25/22 Cowen
- Aerie Pharmaceuticals price target lowered to $25 from $30 at Cowen
- 03/29/22 Chardan
- Applied Genetic transferred with Buy rating at Chardan
- 02/14/22 Stifel
- Stifel keeps Buy rating on Applied Genetic, lowers price target to $10
- 09/24/21 Roth Capital
- Applied Genetic near-term readouts 'major catalysts,' says Roth Capital
- 07/09/21 Chardan
- Applied Genetic coverage transferred at Chardan
- 04/25/22 Morgan Stanley
- Bayer price target raised to EUR 83 from EUR 77 at Morgan Stanley
- 04/05/22 Barclays
- Bayer upgraded to Overweight from Equal Weight at Barclays
- 03/15/22 Barclays
- Bayer price target raised to EUR 60 from EUR 55 at Barclays
- 03/14/22 Jefferies
- Bayer initiated with a Buy at Jefferies
- 04/28/22 Wedbush
- BioMarin price target lowered to $147 from $155 at Wedbush
- 04/25/22 Morgan Stanley
- BioMarin upgraded to Overweight from Equal Weight at Morgan Stanley
- 02/24/22 Piper Sandler
- BioMarin price target raised to $125 from $121 at Piper Sandler
- 01/10/22 JPMorgan
- JPMorgan bullish on BioMarin following CEO 'encouraging' presentation
- 04/13/22 Fermium Research
- DuPont price target lowered to $78 from $87 at Fermium Research
- 04/08/22 JPMorgan
- Celanese added to Analyst Focus List at JPMorgan
- 02/22/22 Deutsche Bank
- Celanese likely to split-up in 2024 or 2025, says Deutsche Bank
- 02/22/22 Piper Sandler
- Celanese downgraded to Underweight from Neutral at Piper Sandler
- 04/06/22 Truist
- Celularity downgraded to Hold from Buy at Truist
- 04/01/22 Oppenheimer
- Celularity price target raised to $10 from $9 at Oppenheimer
- 01/27/22 Oppenheimer
- Celularity initiated with an Outperform at Oppenheimer
- 11/24/21 Morgan Stanley
- Celularity initiated with an Equal Weight at Morgan Stanley
- 03/31/22 BTIG
- Ginkgo Bioworks price target lowered to $6 from $12 at BTIG
- 03/29/22 Cowen
- Ginkgo Bioworks weakness a buying opportunity, says Cowen
- 03/02/22 Cowen
- Ginkgo Bioworks initiated with an Outperform at Cowen
- 02/23/22 Goldman Sachs
- Ginkgo Bioworks initiated with a Neutral at Goldman Sachs
- 04/18/22 Baird
- Editas Medicine price target lowered to $33 from $44 at Baird
- 02/25/22 SVB Leerink
- Editas Medicine price target lowered to $27 from $41 at SVB Leerink
- 02/25/22 Barclays
- Editas Medicine price target lowered to $18 from $39 at Barclays
- 02/25/22 Chardan
- Editas Medicine price target lowered to $60 from $75 at Chardan
HZNP Horizon Therapeutics - 03/14/22 Oppenheimer
- Horizon Therapeutics initiated with an Outperform at Oppenheimer
- 01/26/22 Piper Sandler
- Horizon Therapeutics price target lowered to $133 from $143 at Piper Sandler
- 01/18/22 JPMorgan
- Horizon Therapeutics valuation 'compelling' after selloff, says JPMorgan
- 12/08/21
- Fly Intel: Top five analyst initiations
- 04/29/22 Chardan
- Emergent BioSolutions price target lowered to $65 from $75 at Chardan
- 04/20/22 Credit Suisse
- Johnson & Johnson price target raised to $205 from $200 at Credit Suisse
- 04/20/22 Citi
- Johnson & Johnson price target raised to $210 from $203 at Citi
- 04/19/22 Stifel
- J&J notes more-positive Q1 trends, U.S. Spine 'a relative outlier,' says Stifel
KALA Kala Pharmaceuticals - 03/30/22 Northland
- Kala Pharmaceuticals price target lowered to $4 from $6 at Northland
- 03/30/22 H.C. Wainwright
- Kala Pharmaceuticals price target lowered to $6 from $9 at H.C. Wainwright
- 03/30/22 JPMorgan
- Kala Pharmaceuticals downgraded to Underweight from Neutral at JPMorgan
- 12/15/21 Wedbush
- Kala Pharmaceuticals assumed with an Outperform, $6 target at Wedbush
- 04/13/22 Truist
- Kodiak Sciences price target lowered to $10 from $35 at Truist
- 03/29/22 Chardan
- Kodiak Sciences price target lowered to $19 from $82.50 at Chardan
- 02/28/22 Roth Capital
- Kodiak Sciences price target lowered to $75 from $149 at Roth Capital
- 02/24/22 Truist
- Kodiak Sciences price target lowered to $35 from $147 at Truist
LCTX Lineage Cell Therapeutics - 04/25/22 H.C. Wainwright
- Lineage Cell's PNC program 'an expected and logical move,' says H.C. Wainwright
- 08/19/21 Noble Capital
- Lineage Cell Therapeutics initiated with an Outperform at Noble Capital
- 04/19/22 Cantor Fitzgerald
- ProQR Therapeutics price target lowered to $3.50 from $6.00 at Cantor Fitzgerald
- 04/14/22 Chardan
- ProQR Therapeutics price target lowered to $2.50 from $8 at Chardan
- 03/15/22 Citi
- ProQR Therapeutics price target lowered to $1 from $1.70 at Citi
- 02/14/22 Citi
- ProQR Therapeutics downgraded to Neutral from Buy at Citi
- 04/20/22 Cowen
- Regeneron price target raised to $645 from $640 at Cowen
- 04/20/22 BTIG
- Checkmate Pharmaceuticals downgraded to Neutral from Buy at BTIG
- 04/19/22 Baird
- Decibel could be next target for Regeneron, says Baird
- 04/12/22 Barclays
- Regeneron price target raised to $745 from $700 at Barclays
- 03/29/22 Chardan
- Regenxbio price target lowered to $76 from $90 at Chardan
- 02/10/22 SVB Leerink
- Regenxbio price target lowered to $29 from $35 at SVB Leerink
- 12/15/21
- Fly Intel: Top five analyst initiations
- 12/15/21 Wedbush
- Wedbush initiates Regenxbio with a Neutral rating, price target of $29
- 05/03/22 Piper Sandler
- Piper keeps Overweight rating on Ionis after Biogen's Spinraza beat
- 04/26/22 Stifel
- Arvinas price target lowered to $85 from $93 at Stifel
- 04/19/22 UBS
- Roche downgraded to Sell from Neutral at UBS
- 01/31/22 Jefferies
- Stoke Therapeutics initiated with a Buy at Jefferies
- 12/03/21
- Fly Intel: Top five analyst initiations
- 12/03/21 BofA
- Stoke Therapeutics initiated with a Buy at BofA
- 12/03/21 BofA
- Stoke Therapeutics initiated with a Buy at BofA
- 01/04/22 Roth Capital
- Unity Biotechnology upgraded to Buy at Roth Capital on 2022 clinical plans
- 01/04/22 Roth Capital
- Unity Biotechnology upgraded to Buy from Neutral at Roth Capital
- 12/15/21 Wedbush
- Wedbush bullish on Unity Biotechnology, initiates with an Outperform
- 12/15/21 Wedbush
- Unity Biotechnology assumed with an Outperform at Wedbush
- 03/15/22
- Unity Biotechnology reports Q4 EPS (18), consensus (38c)
- 11/10/21
- Unity Biotechnology reports Q3 EPS (30c), consensus (37c)
- 03/10/22
- Stoke Therapeutics reports Q4 EPS (66c), consensus (62c)
- 11/08/21
- Stoke Therapeutics reports Q3 EPS (61c), consensus (59c)
- 04/25/22
- Roche reports Q1 group sales CHF 16.445B vs. CHF 14.93B last year
- 02/03/22
- Roche sees FY22 core earnings growing in low- to mid-single digit range
- 02/03/22
- Roche reports 2021 core EPS CHF 19.81 vs CHF 19.16
- 03/01/22
- Regenxbio reports Q4 EPS $6.67, consensus $4.71
- 02/04/22
- Regeneron reports Q4 EPS $23.72, consensus $18.02
- 02/03/22
- Notable companies reporting before tomorrow's open
- 11/04/21
- Regeneron reports Q3 EPS $15.37, consensus $9.56
- 02/24/22
- ProQR Therapeutics reports Q4 EPS (EUR0.26) vs. (EUR0.26) last year
- 11/04/21
- ProQR Therapeutics reports Q3 EPS (EUR0.22) vs. (EUR0.26) last year
LCTX Lineage Cell Therapeutics - 03/10/22
- Lineage Cell Therapeutics reports Q4 EPS (17c), consensus (5c)
- 11/10/21
- Lineage Cell Therapeutics reports Q3 EPS (5c), consensus (5c)
- 03/01/22
- Kodiak Sciences reports Q4 EPS ($1.79), consensus ($1.36)
- 11/09/21
- Kodiak Sciences reports Q3 EPS ($1.30), consensus ($1.16)
KALA Kala Pharmaceuticals - 03/29/22
- Kala Pharmaceuticals reports Q4 EPS (68c), consensus (41c)
- 11/15/21
- Kala Pharmaceuticals reports Q3 EPS (43c), consensus (43c)
- 04/19/22
- Johnson & Johnson cuts FY22 adj. EPS view to $10.15-$10.35 from $10.40-$10.60
- 04/19/22
- Johnson & Johnson reports Q1 adjusted EPS $2.67, consensus $2.61
- 04/18/22
- Notable companies reporting before tomorrow's open
HZNP Horizon Therapeutics - 03/01/22
- Horizon Therapeutics sees FY22 revenue $3.9B-$4B, consensus $3.91B
- 03/01/22
- Horizon Therapeutics reports Q4 EPS $1.41, consensus $1.34
- 02/24/22
- Editas Medicine reports Q4 EPS (61c), consensus (72c)
- 11/08/21
- Editas Medicine reports Q3 EPS (57c), consensus (82c)
- 03/28/22
- Ginkgo Bioworks sees FY22 revenue $325M-$340M, consensus $305.75M
- 03/28/22
- Ginkgo Bioworks reports Q4 EPS ($1.10), consensus (4c)
- 01/12/22
- Ginkgo Bioworks sees 2021 revenue above guidance
- 11/15/21
- Ginkgo Bioworks reports Q3 EPS (8c), two estimates (3c)
- 11/12/21
- Celularity reports Q3 EPS 40c, consensus (34c)
- 04/28/22
- Celanese sees FY22 adjusted EPS approaching FY21 adjusted EPS
- 04/28/22
- Celanese reports Q1 adjusted EPS $5.54, consensus $4.52
- 01/27/22
- Celanese sees FY22 EPS 'at least' $15.00, consensus $15.85
- 01/27/22
- Celanese sees Q1 EPS $4.30-$4.60, consensus $4.19
- 04/27/22
- BioMarin backs FY22 revenue view $2.05B-$2.15B, consensus $2.1B
- 04/27/22
- BioMarin reports Q1 GAAP EPS 63c, consensus 17c
- 02/23/22
- BioMarin sees FY22 revenue $2.05B-$2.15B, consensus $2.14B
- 02/23/22
- BioMarin reports Q4 GAAP EPS (32c), consensus (32c)
- 03/01/22
- Bayer sees 2022 group sales of EUR 47B
- 03/01/22
- Bayer reports Q4 core EPS EUR 1.26 vs. EUR 1.32 last year
- 11/09/21
- Bayer reports Q3 core EPS EUR 1.05 vs. EUR 0.81 last year
- 02/14/22
- Applied Genetic reports Q2 EPS (45c), consensus (38c)
- 11/09/21
- Applied Genetic sees cash, cash equivalents funding operations into 2023
- 11/09/21
- Applied Genetic reports Q1 EPS (40c), consensus (35c)
AERI Aerie Pharmaceuticals - 02/24/22
- Aerie Pharmaceuticals reports Q4 EPS $1.09, consensus (67c)
- 11/04/21
- Aerie Pharmaceuticals reports Q3 adjusted EPS (72c), consensus (62c)
ADVM Adverum Biotechnologies - 03/29/22
- Adverum Biotechnologies reports Q4 EPS (35c), consensus (34c)
- 11/04/21
- Adverum Biotechnologies reports Q3 EPS (39c), consensus (37c)
- 03/31/22
- Abeona Therapeutics reports Q4 EPS (45c), consensus (15c)
- 11/15/21
- Abeona Therapeutics reports Q3 EPS (7c), consensus (16c)
- 04/29/22
- AbbVie sees FY22 revenue $59.4B, consensus $60.22B
- 04/29/22
- AbbVie sees Q2 adjusted EPS $3.38-$3.42, consensus $3.50
- 04/29/22
- AbbVie cuts FY22 adjusted EPS view to $13.92-$14.12 from $14.00-$14.20
- 04/29/22
- AbbVie reports Q1 adjusted EPS $3.16, consensus $3.14
|
|
Conference/Events
|
ARVO 2022 to be held in… ARVO 2022 to be held in Denver, CO on May 1-4. ShowHide Related Items >><< - 04/28/22
- Allogene Therapeutics appoints Lundeen as Chief People Officer
- 04/19/22
- Unity Biotechnology doses first patient in ENVISION study of UBX1325
- 04/12/22
- Unity Biotechnology completes enrollment in BEHOLD study
- 03/15/22
- Unity Biotechnology expects cash to fund operations into 1Q23
- 05/02/22
- Stoke Therapeutics presents new in-vivo data for STK-002
- 12/03/21
- Stoke Therapeutics presents data from Phase 1/2a MONARCH study of STK-001
- 04/29/22
- Genentech announces new three-year data from FIREFISH study
- 04/25/22
- Roche sees FY22 sales stable or up in low single digits
- 04/25/22
- Roche confirms outlook for 2022
- 04/22/22
- Roche reports CHMP recommends approval of Tecentriq as adjuvant NSCLC treatment
- 02/09/22
- Regenxbio reporting 'additional positive interim data' from MPS II trial
- 01/06/22
- Regenxbio announces FDA clearance of IND for clinical trial of RGX-202
- 11/22/21
- Regenxbio announces FDA Orphan Drug Designation for RGX-202
- 11/12/21
- Regenxbio reports additional positive interim data from trials of RGX-314
- 04/19/22
- Regeneron to acquire Checkmate Pharmaceuticals for $10.50 per share in cash
- 04/19/22
- Regeneron to acquire Checkmate Pharmaceuticals for $10.50 per share in cash
- 04/19/22
- Regeneron to acquire Checkmate Pharmaceuticals for $10.50 per share in cash
- 04/19/22
- Regeneron to acquire Checkmate Pharmaceuticals for $10.50 per share in cash
- 04/13/22
- ProQR Therapeutics announces additional sepofarsen Illuminate trial analyses
- 04/13/22
- ProQR Therapeutics expects cash to fund operations into 2025
- 04/13/22
- ProQR Therapeutics to reduce workforce by 30%, CSO Naveed Shams to depart
- 04/13/22
- ProQR Therapeutics suspends development of QR-1123, QR-504a
LCTX Lineage Cell Therapeutics - 04/25/22
- Lineage Cell Therapeutics announces new cell therapy development program
- 04/20/22
- Enochian Biosciences appoints Binette as EVP for Research, Development
- 04/13/22
- Lineage Cell announces Cancer Research UK completes enrollment for VAC2 trial
- 12/20/21
- Lineage Cell Therapeutics enters license agreement with Roche, Genentech
- 02/23/22
- Kodiak Sciences announces KSI-301 trial did not meet primary efficacy endpoint
- 02/03/22
- Kodiak Sciences completes enrollment in GLEAM, GLIMMER trials
- 12/16/21
- Kodiak Sciences completes enrollment in BEACON trial
KALA Kala Pharmaceuticals - 05/01/22
- Kala Pharmaceuticals to present clinical data for KPI-012 at ARVO Annual Meeting
- 03/29/22
- Kala Pharmaceuticals expects cash to fund operations into Q2 of 2023
- 03/08/22
- Kala Pharmaceuticals announces EYSUVIS now covered by UnitedHealthcare, Cigna
- 11/15/21
- Kala Pharmaceuticals acquires Combangio
- 05/02/22
- FDA announces tentative advisory committee meetings on COVID-19 vaccines
- 05/02/22
- Roivant Sciences announces collaborations in targeted protein degradation
- 04/19/22
- Johnson & Johnson announces $77M opioid settlement with Alabama
- 04/19/22
- Johnson & Johnson says continues to invest in R&D at 'competitive levels'
HZNP Horizon Therapeutics - 05/02/22
- Roivant Sciences appoints Srini Ramanathan as CDO
- 05/02/22
- Horizon Therapeutics announces EC approval of Uplinza
- 04/11/22
- Eton Pharmaceuticals CFO Wilson Troutman to retire, James Gruber to succeed
- 03/31/22
- Horizon says UPLIZNA effective in patients with newly-presenting NMOSD
- 04/26/22
- Editas Medicine receives FDA Rare Pediatric Disease designation for EDIT-301
- 04/14/22
- Editas Medicine appoints Gilmore O'Neill as CEO
- 04/11/22
- Editas Medicine announces dosing of first pediatric patient in BRILLIANCE trial
- 04/08/22
- Editas Medicine reports engineered iNK cell preclinical data
- 04/26/22
- Cathie Wood's ARK Investment bought 1.3M shares of Ginkgo Bioworks today
- 04/25/22
- Cathie Wood's ARK Investment bought 232.6K shares of Ginkgo Bioworks today
- 04/20/22
- Cathie Wood's ARK Investment bought 881K shares of Ginkgo Bioworks today
- 02/15/22
- FDA grants Celularity fast track designation for CYNK-101
- 02/14/22
- Celularity's treatment of gastric junction cancer gets FDA orphan designation
- 01/18/22
- Celularity receives Fast Track Designation for CYNK-101
- 12/27/21
- Celularity receives Fast Track Designation for CYNK-001
- $145.86 /
-1.025 (-0.70%) - 03/31/22
- Celanese sees EPS accretion from KEP restructuring 15-20c over three years
- 02/18/22
- DuPont to divest majority of mobility and materials segment to Celanese for $11B
- 02/18/22
- Celanese to acquire majority of DuPont M&M business for $11B in cash
- 02/07/22
- Linde expands existing agreement with Celanese
- 03/17/22
- BioMarin's hemophilia A candidate shows efficacy in published article
- 02/24/22
- BioMarin trading resumes
- 02/24/22
- BioMarin trading halted, volatility trading pause
- 02/17/22
- BioMarin provides updates on progress in gene therapy programs
- 04/22/22
- Ginkgo Bioworks announces partnership with Bayer
- 04/12/22
- ALX Oncology appoints Canamasas to board of directors
- 04/11/22
- 22nd Century appoints Calvin Treat as CSO
- 03/24/22
- Bayer's Monsanto settles with Ohio Attorney General for $80M
- 03/22/22
- Applied Genetic announces pricing of public offering of common stock
- 02/14/22
- Applied Genetic expects cash to fund operations into 2023
- 02/08/22
- Applied Genetic announces interim data from studies of AGTC-401, AGTC-402
- 01/11/22
- Applied Genetic exceeds enrollment target in SKYLINE trial of AGTC-501
AERI Aerie Pharmaceuticals - 03/21/22
- Ocugen names Jessica Crespo as Chief Accounting Officer
- 03/18/22
- Aerie Pharmaceuticals announces Peter Lang as CFO
- 02/24/22
- Aerie Pharmaceuticals sees FY Glaucoma franchise net product revenues up 16%-25%
- 02/24/22
- Aerie Pharmaceuticals names Gary Sternberg as Chief Medical Officer
ADVM Adverum Biotechnologies - 05/01/22
- Adverum presents additional efficacy, safety data from OPTIC trial of ADVM-022
- 04/06/22
- Adverum proceeds with IND amendment for wet AMD trial after FDA Type C feedback
- 03/29/22
- Nkarta Adverum appoints Thedinga to board of directors
- 02/07/22
- Adverum Biotechnologies appoints Richard Beckman as CMO
- 04/29/22
- Abeona Therapeutics announces pricing of $25M private placement
- 03/14/22
- Abeona Therapeutics reaches target enrollment in Phase 3 VIITAL study of EB-101
- 03/09/22
- Abeona Therapeutics CFO Edward Carr resigns
- 12/22/21
- Abeona issues letter to shareholders on 2022 anticipated milestones
- 04/29/22
- AbbVie's RINVOQ approved by FDA for treatment of active AS
- 04/29/22
- AbbVie says no plans to cut R&D investments in 2023
- 04/29/22
- AbbVie says cystic fibrosis combination drug missed study goal
- 04/29/22
- AbbVie says confident in long-term fundamentals of business
- 05/02/22 Morgan Stanley
- AbbVie's recent weakness a buying opportunity, says Morgan Stanley
- 05/02/22 Wells Fargo
- AbbVie price target raised to $200 from $165 at Wells Fargo
- 05/02/22 Cowen
- Genmab initiated with a Market Perform at Cowen
- 05/02/22 JPMorgan
- AbbVie selloff Friday 'very much overdone,' says JPMorgan
- 11/30/21 SVB Leerink
- Abeona Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
- 11/29/21 H.C. Wainwright
- Abeona Therapeutics price target lowered to $4 from $5 at H.C. Wainwright
- 07/19/21 H.C. Wainwright
- Abeona Therapeutics price target lowered to $5 from $8 at H.C. Wainwright
ADVM Adverum Biotechnologies - 03/29/22 Chardan
- Adverum Biotechnologies transferred with Neutral at Chardan
- 07/23/21
- Fly Intel: Top five analyst downgrades
- 07/23/21 Goldman Sachs
- Adverum Biotechnologies downgraded to Neutral from Buy at Goldman Sachs
- 07/23/21 SVB Leerink
- Adverum Biotechnologies price target lowered to $2 from $5
AERI Aerie Pharmaceuticals - 02/28/22 Citi
- Aerie Pharmaceuticals price target lowered to $13 from $23 at Citi
- 02/25/22 Cowen
- Aerie Pharmaceuticals price target lowered to $25 from $30 at Cowen
- 03/29/22 Chardan
- Applied Genetic transferred with Buy rating at Chardan
- 02/14/22 Stifel
- Stifel keeps Buy rating on Applied Genetic, lowers price target to $10
- 09/24/21 Roth Capital
- Applied Genetic near-term readouts 'major catalysts,' says Roth Capital
- 07/09/21 Chardan
- Applied Genetic coverage transferred at Chardan
- 04/25/22 Morgan Stanley
- Bayer price target raised to EUR 83 from EUR 77 at Morgan Stanley
- 04/05/22 Barclays
- Bayer upgraded to Overweight from Equal Weight at Barclays
- 03/15/22 Barclays
- Bayer price target raised to EUR 60 from EUR 55 at Barclays
- 03/14/22 Jefferies
- Bayer initiated with a Buy at Jefferies
- 04/28/22 Wedbush
- BioMarin price target lowered to $147 from $155 at Wedbush
- 04/25/22 Morgan Stanley
- BioMarin upgraded to Overweight from Equal Weight at Morgan Stanley
- 02/24/22 Piper Sandler
- BioMarin price target raised to $125 from $121 at Piper Sandler
- 01/10/22 JPMorgan
- JPMorgan bullish on BioMarin following CEO 'encouraging' presentation
- $145.86 /
-1.025 (-0.70%) - 04/13/22 Fermium Research
- DuPont price target lowered to $78 from $87 at Fermium Research
- 04/08/22 JPMorgan
- Celanese added to Analyst Focus List at JPMorgan
- 02/22/22 Deutsche Bank
- Celanese likely to split-up in 2024 or 2025, says Deutsche Bank
- 02/22/22 Piper Sandler
- Celanese downgraded to Underweight from Neutral at Piper Sandler
- 04/06/22 Truist
- Celularity downgraded to Hold from Buy at Truist
- 04/01/22 Oppenheimer
- Celularity price target raised to $10 from $9 at Oppenheimer
- 01/27/22 Oppenheimer
- Celularity initiated with an Outperform at Oppenheimer
- 11/24/21 Morgan Stanley
- Celularity initiated with an Equal Weight at Morgan Stanley
- 03/31/22 BTIG
- Ginkgo Bioworks price target lowered to $6 from $12 at BTIG
- 03/29/22 Cowen
- Ginkgo Bioworks weakness a buying opportunity, says Cowen
- 03/02/22 Cowen
- Ginkgo Bioworks initiated with an Outperform at Cowen
- 02/23/22 Goldman Sachs
- Ginkgo Bioworks initiated with a Neutral at Goldman Sachs
- 04/18/22 Baird
- Editas Medicine price target lowered to $33 from $44 at Baird
- 02/25/22 SVB Leerink
- Editas Medicine price target lowered to $27 from $41 at SVB Leerink
- 02/25/22 Barclays
- Editas Medicine price target lowered to $18 from $39 at Barclays
- 02/25/22 Chardan
- Editas Medicine price target lowered to $60 from $75 at Chardan
HZNP Horizon Therapeutics - 03/14/22 Oppenheimer
- Horizon Therapeutics initiated with an Outperform at Oppenheimer
- 01/26/22 Piper Sandler
- Horizon Therapeutics price target lowered to $133 from $143 at Piper Sandler
- 01/18/22 JPMorgan
- Horizon Therapeutics valuation 'compelling' after selloff, says JPMorgan
- 12/08/21
- Fly Intel: Top five analyst initiations
- 04/29/22 Chardan
- Emergent BioSolutions price target lowered to $65 from $75 at Chardan
- 04/20/22 Credit Suisse
- Johnson & Johnson price target raised to $205 from $200 at Credit Suisse
- 04/20/22 Citi
- Johnson & Johnson price target raised to $210 from $203 at Citi
- 04/19/22 Stifel
- J&J notes more-positive Q1 trends, U.S. Spine 'a relative outlier,' says Stifel
KALA Kala Pharmaceuticals - 03/30/22 Northland
- Kala Pharmaceuticals price target lowered to $4 from $6 at Northland
- 03/30/22 H.C. Wainwright
- Kala Pharmaceuticals price target lowered to $6 from $9 at H.C. Wainwright
- 03/30/22 JPMorgan
- Kala Pharmaceuticals downgraded to Underweight from Neutral at JPMorgan
- 12/15/21 Wedbush
- Kala Pharmaceuticals assumed with an Outperform, $6 target at Wedbush
- 04/13/22 Truist
- Kodiak Sciences price target lowered to $10 from $35 at Truist
- 03/29/22 Chardan
- Kodiak Sciences price target lowered to $19 from $82.50 at Chardan
- 02/28/22 Roth Capital
- Kodiak Sciences price target lowered to $75 from $149 at Roth Capital
- 02/24/22 Truist
- Kodiak Sciences price target lowered to $35 from $147 at Truist
LCTX Lineage Cell Therapeutics - 04/25/22 H.C. Wainwright
- Lineage Cell's PNC program 'an expected and logical move,' says H.C. Wainwright
- 08/19/21 Noble Capital
- Lineage Cell Therapeutics initiated with an Outperform at Noble Capital
- 04/19/22 Cantor Fitzgerald
- ProQR Therapeutics price target lowered to $3.50 from $6.00 at Cantor Fitzgerald
- 04/14/22 Chardan
- ProQR Therapeutics price target lowered to $2.50 from $8 at Chardan
- 03/15/22 Citi
- ProQR Therapeutics price target lowered to $1 from $1.70 at Citi
- 02/14/22 Citi
- ProQR Therapeutics downgraded to Neutral from Buy at Citi
- 04/20/22 Cowen
- Regeneron price target raised to $645 from $640 at Cowen
- 04/20/22 BTIG
- Checkmate Pharmaceuticals downgraded to Neutral from Buy at BTIG
- 04/19/22 Baird
- Decibel could be next target for Regeneron, says Baird
- 04/12/22 Barclays
- Regeneron price target raised to $745 from $700 at Barclays
- 03/29/22 Chardan
- Regenxbio price target lowered to $76 from $90 at Chardan
- 02/10/22 SVB Leerink
- Regenxbio price target lowered to $29 from $35 at SVB Leerink
- 12/15/21
- Fly Intel: Top five analyst initiations
- 12/15/21 Wedbush
- Wedbush initiates Regenxbio with a Neutral rating, price target of $29
- 04/26/22 Stifel
- Arvinas price target lowered to $85 from $93 at Stifel
- 04/19/22 UBS
- Roche downgraded to Sell from Neutral at UBS
- 04/14/22 Barclays
- Roche price target raised to CHF 450 from CHF 415 at Barclays
- 01/31/22 Jefferies
- Stoke Therapeutics initiated with a Buy at Jefferies
- 12/03/21
- Fly Intel: Top five analyst initiations
- 12/03/21 BofA
- Stoke Therapeutics initiated with a Buy at BofA
- 12/03/21 BofA
- Stoke Therapeutics initiated with a Buy at BofA
- 01/04/22 Roth Capital
- Unity Biotechnology upgraded to Buy at Roth Capital on 2022 clinical plans
- 01/04/22 Roth Capital
- Unity Biotechnology upgraded to Buy from Neutral at Roth Capital
- 12/15/21 Wedbush
- Wedbush bullish on Unity Biotechnology, initiates with an Outperform
- 12/15/21 Wedbush
- Unity Biotechnology assumed with an Outperform at Wedbush
- 03/15/22
- Unity Biotechnology reports Q4 EPS (18), consensus (38c)
- 11/10/21
- Unity Biotechnology reports Q3 EPS (30c), consensus (37c)
- 03/10/22
- Stoke Therapeutics reports Q4 EPS (66c), consensus (62c)
- 11/08/21
- Stoke Therapeutics reports Q3 EPS (61c), consensus (59c)
- 04/25/22
- Roche reports Q1 group sales CHF 16.445B vs. CHF 14.93B last year
- 02/03/22
- Roche sees FY22 core earnings growing in low- to mid-single digit range
- 02/03/22
- Roche reports 2021 core EPS CHF 19.81 vs CHF 19.16
- 03/01/22
- Regenxbio reports Q4 EPS $6.67, consensus $4.71
- 02/04/22
- Regeneron reports Q4 EPS $23.72, consensus $18.02
- 02/03/22
- Notable companies reporting before tomorrow's open
- 11/04/21
- Regeneron reports Q3 EPS $15.37, consensus $9.56
- 02/24/22
- ProQR Therapeutics reports Q4 EPS (EUR0.26) vs. (EUR0.26) last year
- 11/04/21
- ProQR Therapeutics reports Q3 EPS (EUR0.22) vs. (EUR0.26) last year
LCTX Lineage Cell Therapeutics - 03/10/22
- Lineage Cell Therapeutics reports Q4 EPS (17c), consensus (5c)
- 11/10/21
- Lineage Cell Therapeutics reports Q3 EPS (5c), consensus (5c)
- 03/01/22
- Kodiak Sciences reports Q4 EPS ($1.79), consensus ($1.36)
- 11/09/21
- Kodiak Sciences reports Q3 EPS ($1.30), consensus ($1.16)
KALA Kala Pharmaceuticals - 03/29/22
- Kala Pharmaceuticals reports Q4 EPS (68c), consensus (41c)
- 11/15/21
- Kala Pharmaceuticals reports Q3 EPS (43c), consensus (43c)
- 04/19/22
- Johnson & Johnson cuts FY22 adj. EPS view to $10.15-$10.35 from $10.40-$10.60
- 04/19/22
- Johnson & Johnson reports Q1 adjusted EPS $2.67, consensus $2.61
- 04/18/22
- Notable companies reporting before tomorrow's open
HZNP Horizon Therapeutics - 03/01/22
- Horizon Therapeutics sees FY22 revenue $3.9B-$4B, consensus $3.91B
- 03/01/22
- Horizon Therapeutics reports Q4 EPS $1.41, consensus $1.34
- 11/03/21
- Horizon Therapeutics sees FY21 revenue $3.16B-$3.21B, consensus $3.12B
- 11/03/21
- Horizon Therapeutics reports Q3 EPS $1.75, consensus $1.54
- 02/24/22
- Editas Medicine reports Q4 EPS (61c), consensus (72c)
- 11/08/21
- Editas Medicine reports Q3 EPS (57c), consensus (82c)
- 03/28/22
- Ginkgo Bioworks sees FY22 revenue $325M-$340M, consensus $305.75M
- 03/28/22
- Ginkgo Bioworks reports Q4 EPS ($1.10), consensus (4c)
- 01/12/22
- Ginkgo Bioworks sees 2021 revenue above guidance
- 11/15/21
- Ginkgo Bioworks reports Q3 EPS (8c), two estimates (3c)
- 11/12/21
- Celularity reports Q3 EPS 40c, consensus (34c)
- $145.86 /
-1.025 (-0.70%) - 04/28/22
- Celanese sees FY22 adjusted EPS approaching FY21 adjusted EPS
- 04/28/22
- Celanese reports Q1 adjusted EPS $5.54, consensus $4.52
- 01/27/22
- Celanese sees FY22 EPS 'at least' $15.00, consensus $15.85
- 01/27/22
- Celanese sees Q1 EPS $4.30-$4.60, consensus $4.19
- 04/27/22
- BioMarin backs FY22 revenue view $2.05B-$2.15B, consensus $2.1B
- 04/27/22
- BioMarin reports Q1 GAAP EPS 63c, consensus 17c
- 02/23/22
- BioMarin sees FY22 revenue $2.05B-$2.15B, consensus $2.14B
- 02/23/22
- BioMarin reports Q4 GAAP EPS (32c), consensus (32c)
- 03/01/22
- Bayer sees 2022 group sales of EUR 47B
- 03/01/22
- Bayer reports Q4 core EPS EUR 1.26 vs. EUR 1.32 last year
- 11/09/21
- Bayer reports Q3 core EPS EUR 1.05 vs. EUR 0.81 last year
- 02/14/22
- Applied Genetic reports Q2 EPS (45c), consensus (38c)
- 11/09/21
- Applied Genetic sees cash, cash equivalents funding operations into 2023
- 11/09/21
- Applied Genetic reports Q1 EPS (40c), consensus (35c)
AERI Aerie Pharmaceuticals - 02/24/22
- Aerie Pharmaceuticals reports Q4 EPS $1.09, consensus (67c)
- 11/04/21
- Aerie Pharmaceuticals reports Q3 adjusted EPS (72c), consensus (62c)
ADVM Adverum Biotechnologies - 03/29/22
- Adverum Biotechnologies reports Q4 EPS (35c), consensus (34c)
- 11/04/21
- Adverum Biotechnologies reports Q3 EPS (39c), consensus (37c)
- 03/31/22
- Abeona Therapeutics reports Q4 EPS (45c), consensus (15c)
- 11/15/21
- Abeona Therapeutics reports Q3 EPS (7c), consensus (16c)
- 04/29/22
- AbbVie sees FY22 revenue $59.4B, consensus $60.22B
- 04/29/22
- AbbVie sees Q2 adjusted EPS $3.38-$3.42, consensus $3.50
- 04/29/22
- AbbVie cuts FY22 adjusted EPS view to $13.92-$14.12 from $14.00-$14.20
- 04/29/22
- AbbVie reports Q1 adjusted EPS $3.16, consensus $3.14
|
|
Conference/Events
|
ARVO 2022 to be held in… ARVO 2022 to be held in Denver, CO on May 1-4. ShowHide Related Items >><< - 04/28/22
- Allogene Therapeutics appoints Lundeen as Chief People Officer
- 04/19/22
- Unity Biotechnology doses first patient in ENVISION study of UBX1325
- 04/12/22
- Unity Biotechnology completes enrollment in BEHOLD study
- 03/15/22
- Unity Biotechnology expects cash to fund operations into 1Q23
- 12/03/21
- Stoke Therapeutics presents data from Phase 1/2a MONARCH study of STK-001
- 04/29/22
- Genentech announces new three-year data from FIREFISH study
- 04/25/22
- Roche sees FY22 sales stable or up in low single digits
- 04/25/22
- Roche confirms outlook for 2022
- 04/22/22
- Roche reports CHMP recommends approval of Tecentriq as adjuvant NSCLC treatment
- 02/09/22
- Regenxbio reporting 'additional positive interim data' from MPS II trial
- 01/06/22
- Regenxbio announces FDA clearance of IND for clinical trial of RGX-202
- 11/22/21
- Regenxbio announces FDA Orphan Drug Designation for RGX-202
- 11/12/21
- Regenxbio reports additional positive interim data from trials of RGX-314
- $658.67 /
-0.225 (-0.03%) - 04/19/22
- Regeneron to acquire Checkmate Pharmaceuticals for $10.50 per share in cash
- 04/19/22
- Regeneron to acquire Checkmate Pharmaceuticals for $10.50 per share in cash
- 04/19/22
- Regeneron to acquire Checkmate Pharmaceuticals for $10.50 per share in cash
- 04/19/22
- Regeneron to acquire Checkmate Pharmaceuticals for $10.50 per share in cash
- 04/13/22
- ProQR Therapeutics announces additional sepofarsen Illuminate trial analyses
- 04/13/22
- ProQR Therapeutics expects cash to fund operations into 2025
- 04/13/22
- ProQR Therapeutics to reduce workforce by 30%, CSO Naveed Shams to depart
- 04/13/22
- ProQR Therapeutics suspends development of QR-1123, QR-504a
LCTX Lineage Cell Therapeutics - 04/25/22
- Lineage Cell Therapeutics announces new cell therapy development program
- 04/20/22
- Enochian Biosciences appoints Binette as EVP for Research, Development
- 04/13/22
- Lineage Cell announces Cancer Research UK completes enrollment for VAC2 trial
- 12/20/21
- Lineage Cell Therapeutics enters license agreement with Roche, Genentech
- 02/23/22
- Kodiak Sciences announces KSI-301 trial did not meet primary efficacy endpoint
- 02/03/22
- Kodiak Sciences completes enrollment in GLEAM, GLIMMER trials
- 12/16/21
- Kodiak Sciences completes enrollment in BEACON trial
KALA Kala Pharmaceuticals - 05/01/22
- Kala Pharmaceuticals to present clinical data for KPI-012 at ARVO Annual Meeting
- 03/29/22
- Kala Pharmaceuticals expects cash to fund operations into Q2 of 2023
- 03/08/22
- Kala Pharmaceuticals announces EYSUVIS now covered by UnitedHealthcare, Cigna
- 11/15/21
- Kala Pharmaceuticals acquires Combangio
- $180.45 /
-0.185 (-0.10%) - 05/02/22
- Roivant Sciences announces collaborations in targeted protein degradation
- 04/19/22
- Johnson & Johnson announces $77M opioid settlement with Alabama
- 04/19/22
- Johnson & Johnson says continues to invest in R&D at 'competitive levels'
- 04/19/22
- Johnson & Johnson sees 'external supply constraints' in Consumer Health unit
HZNP Horizon Therapeutics - 05/02/22
- Roivant Sciences appoints Srini Ramanathan as CDO
- 05/02/22
- Horizon Therapeutics announces EC approval of Uplinza
- 04/11/22
- Eton Pharmaceuticals CFO Wilson Troutman to retire, James Gruber to succeed
- 03/31/22
- Horizon says UPLIZNA effective in patients with newly-presenting NMOSD
- 04/26/22
- Editas Medicine receives FDA Rare Pediatric Disease designation for EDIT-301
- 04/14/22
- Editas Medicine appoints Gilmore O'Neill as CEO
- 04/11/22
- Editas Medicine announces dosing of first pediatric patient in BRILLIANCE trial
- 04/08/22
- Editas Medicine reports engineered iNK cell preclinical data
- 04/26/22
- Cathie Wood's ARK Investment bought 1.3M shares of Ginkgo Bioworks today
- 04/25/22
- Cathie Wood's ARK Investment bought 232.6K shares of Ginkgo Bioworks today
- 04/20/22
- Cathie Wood's ARK Investment bought 881K shares of Ginkgo Bioworks today
- 02/15/22
- FDA grants Celularity fast track designation for CYNK-101
- 02/14/22
- Celularity's treatment of gastric junction cancer gets FDA orphan designation
- 01/18/22
- Celularity receives Fast Track Designation for CYNK-101
- 12/27/21
- Celularity receives Fast Track Designation for CYNK-001
- 03/31/22
- Celanese sees EPS accretion from KEP restructuring 15-20c over three years
- 02/18/22
- DuPont to divest majority of mobility and materials segment to Celanese for $11B
- 02/18/22
- Celanese to acquire majority of DuPont M&M business for $11B in cash
- 02/07/22
- Linde expands existing agreement with Celanese
- 03/17/22
- BioMarin's hemophilia A candidate shows efficacy in published article
- 02/24/22
- BioMarin trading resumes
- 02/24/22
- BioMarin trading halted, volatility trading pause
- 02/17/22
- BioMarin provides updates on progress in gene therapy programs
- 04/22/22
- Ginkgo Bioworks announces partnership with Bayer
- 04/12/22
- ALX Oncology appoints Canamasas to board of directors
- 04/11/22
- 22nd Century appoints Calvin Treat as CSO
- 03/24/22
- Bayer's Monsanto settles with Ohio Attorney General for $80M
- 03/22/22
- Applied Genetic announces pricing of public offering of common stock
- 02/14/22
- Applied Genetic expects cash to fund operations into 2023
- 02/08/22
- Applied Genetic announces interim data from studies of AGTC-401, AGTC-402
- 01/11/22
- Applied Genetic exceeds enrollment target in SKYLINE trial of AGTC-501
AERI Aerie Pharmaceuticals - 03/21/22
- Ocugen names Jessica Crespo as Chief Accounting Officer
- 03/18/22
- Aerie Pharmaceuticals announces Peter Lang as CFO
- 02/24/22
- Aerie Pharmaceuticals sees FY Glaucoma franchise net product revenues up 16%-25%
- 02/24/22
- Aerie Pharmaceuticals names Gary Sternberg as Chief Medical Officer
ADVM Adverum Biotechnologies - 05/01/22
- Adverum presents additional efficacy, safety data from OPTIC trial of ADVM-022
- 04/06/22
- Adverum proceeds with IND amendment for wet AMD trial after FDA Type C feedback
- 03/29/22
- Nkarta Adverum appoints Thedinga to board of directors
- 02/07/22
- Adverum Biotechnologies appoints Richard Beckman as CMO
- 04/29/22
- Abeona Therapeutics announces pricing of $25M private placement
- 03/14/22
- Abeona Therapeutics reaches target enrollment in Phase 3 VIITAL study of EB-101
- 03/09/22
- Abeona Therapeutics CFO Edward Carr resigns
- 12/22/21
- Abeona issues letter to shareholders on 2022 anticipated milestones
- 04/29/22
- AbbVie's RINVOQ approved by FDA for treatment of active AS
- 04/29/22
- AbbVie says no plans to cut R&D investments in 2023
- 04/29/22
- AbbVie says cystic fibrosis combination drug missed study goal
- 04/29/22
- AbbVie says confident in long-term fundamentals of business
- 05/02/22 Morgan Stanley
- AbbVie's recent weakness a buying opportunity, says Morgan Stanley
- 05/02/22 Wells Fargo
- AbbVie price target raised to $200 from $165 at Wells Fargo
- 05/02/22 Cowen
- Genmab initiated with a Market Perform at Cowen
- 05/02/22 JPMorgan
- AbbVie selloff Friday 'very much overdone,' says JPMorgan
- 11/30/21 SVB Leerink
- Abeona Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
- 11/29/21 H.C. Wainwright
- Abeona Therapeutics price target lowered to $4 from $5 at H.C. Wainwright
- 07/19/21 H.C. Wainwright
- Abeona Therapeutics price target lowered to $5 from $8 at H.C. Wainwright
ADVM Adverum Biotechnologies - 03/29/22 Chardan
- Adverum Biotechnologies transferred with Neutral at Chardan
- 07/23/21
- Fly Intel: Top five analyst downgrades
- 07/23/21 Goldman Sachs
- Adverum Biotechnologies downgraded to Neutral from Buy at Goldman Sachs
- 07/23/21 SVB Leerink
- Adverum Biotechnologies price target lowered to $2 from $5
AERI Aerie Pharmaceuticals - 02/28/22 Citi
- Aerie Pharmaceuticals price target lowered to $13 from $23 at Citi
- 02/25/22 Cowen
- Aerie Pharmaceuticals price target lowered to $25 from $30 at Cowen
- 03/29/22 Chardan
- Applied Genetic transferred with Buy rating at Chardan
- 02/14/22 Stifel
- Stifel keeps Buy rating on Applied Genetic, lowers price target to $10
- 09/24/21 Roth Capital
- Applied Genetic near-term readouts 'major catalysts,' says Roth Capital
- 07/09/21 Chardan
- Applied Genetic coverage transferred at Chardan
- 04/25/22 Morgan Stanley
- Bayer price target raised to EUR 83 from EUR 77 at Morgan Stanley
- 04/05/22 Barclays
- Bayer upgraded to Overweight from Equal Weight at Barclays
- 03/15/22 Barclays
- Bayer price target raised to EUR 60 from EUR 55 at Barclays
- 03/14/22 Jefferies
- Bayer initiated with a Buy at Jefferies
- 04/28/22 Wedbush
- BioMarin price target lowered to $147 from $155 at Wedbush
- 04/25/22 Morgan Stanley
- BioMarin upgraded to Overweight from Equal Weight at Morgan Stanley
- 02/24/22 Piper Sandler
- BioMarin price target raised to $125 from $121 at Piper Sandler
- 01/10/22 JPMorgan
- JPMorgan bullish on BioMarin following CEO 'encouraging' presentation
- 04/13/22 Fermium Research
- DuPont price target lowered to $78 from $87 at Fermium Research
- 04/08/22 JPMorgan
- Celanese added to Analyst Focus List at JPMorgan
- 02/22/22 Deutsche Bank
- Celanese likely to split-up in 2024 or 2025, says Deutsche Bank
- 02/22/22 Piper Sandler
- Celanese downgraded to Underweight from Neutral at Piper Sandler
- 04/06/22 Truist
- Celularity downgraded to Hold from Buy at Truist
- 04/01/22 Oppenheimer
- Celularity price target raised to $10 from $9 at Oppenheimer
- 01/27/22 Oppenheimer
- Celularity initiated with an Outperform at Oppenheimer
- 11/24/21 Morgan Stanley
- Celularity initiated with an Equal Weight at Morgan Stanley
- 03/31/22 BTIG
- Ginkgo Bioworks price target lowered to $6 from $12 at BTIG
- 03/29/22 Cowen
- Ginkgo Bioworks weakness a buying opportunity, says Cowen
- 03/02/22 Cowen
- Ginkgo Bioworks initiated with an Outperform at Cowen
- 02/23/22 Goldman Sachs
- Ginkgo Bioworks initiated with a Neutral at Goldman Sachs
- 04/18/22 Baird
- Editas Medicine price target lowered to $33 from $44 at Baird
- 02/25/22 SVB Leerink
- Editas Medicine price target lowered to $27 from $41 at SVB Leerink
- 02/25/22 Barclays
- Editas Medicine price target lowered to $18 from $39 at Barclays
- 02/25/22 Chardan
- Editas Medicine price target lowered to $60 from $75 at Chardan
HZNP Horizon Therapeutics - 03/14/22 Oppenheimer
- Horizon Therapeutics initiated with an Outperform at Oppenheimer
- 01/26/22 Piper Sandler
- Horizon Therapeutics price target lowered to $133 from $143 at Piper Sandler
- 01/18/22 JPMorgan
- Horizon Therapeutics valuation 'compelling' after selloff, says JPMorgan
- 12/08/21
- Fly Intel: Top five analyst initiations
- $180.45 /
-0.185 (-0.10%) - 04/29/22 Chardan
- Emergent BioSolutions price target lowered to $65 from $75 at Chardan
- 04/20/22 Credit Suisse
- Johnson & Johnson price target raised to $205 from $200 at Credit Suisse
- 04/20/22 Citi
- Johnson & Johnson price target raised to $210 from $203 at Citi
- 04/19/22 Stifel
- J&J notes more-positive Q1 trends, U.S. Spine 'a relative outlier,' says Stifel
KALA Kala Pharmaceuticals - 03/30/22 Northland
- Kala Pharmaceuticals price target lowered to $4 from $6 at Northland
- 03/30/22 H.C. Wainwright
- Kala Pharmaceuticals price target lowered to $6 from $9 at H.C. Wainwright
- 03/30/22 JPMorgan
- Kala Pharmaceuticals downgraded to Underweight from Neutral at JPMorgan
- 12/15/21 Wedbush
- Kala Pharmaceuticals assumed with an Outperform, $6 target at Wedbush
- 04/13/22 Truist
- Kodiak Sciences price target lowered to $10 from $35 at Truist
- 03/29/22 Chardan
- Kodiak Sciences price target lowered to $19 from $82.50 at Chardan
- 02/28/22 Roth Capital
- Kodiak Sciences price target lowered to $75 from $149 at Roth Capital
- 02/24/22 Truist
- Kodiak Sciences price target lowered to $35 from $147 at Truist
LCTX Lineage Cell Therapeutics - 04/25/22 H.C. Wainwright
- Lineage Cell's PNC program 'an expected and logical move,' says H.C. Wainwright
- 08/19/21 Noble Capital
- Lineage Cell Therapeutics initiated with an Outperform at Noble Capital
- 04/19/22 Cantor Fitzgerald
- ProQR Therapeutics price target lowered to $3.50 from $6.00 at Cantor Fitzgerald
- 04/14/22 Chardan
- ProQR Therapeutics price target lowered to $2.50 from $8 at Chardan
- 03/15/22 Citi
- ProQR Therapeutics price target lowered to $1 from $1.70 at Citi
- 02/14/22 Citi
- ProQR Therapeutics downgraded to Neutral from Buy at Citi
- $658.67 /
-0.225 (-0.03%) - 04/20/22 Cowen
- Regeneron price target raised to $645 from $640 at Cowen
- 04/20/22 BTIG
- Checkmate Pharmaceuticals downgraded to Neutral from Buy at BTIG
- 04/19/22 Baird
- Decibel could be next target for Regeneron, says Baird
- 04/12/22 Barclays
- Regeneron price target raised to $745 from $700 at Barclays
- 03/29/22 Chardan
- Regenxbio price target lowered to $76 from $90 at Chardan
- 02/10/22 SVB Leerink
- Regenxbio price target lowered to $29 from $35 at SVB Leerink
- 12/15/21
- Fly Intel: Top five analyst initiations
- 12/15/21 Wedbush
- Wedbush initiates Regenxbio with a Neutral rating, price target of $29
- 04/26/22 Stifel
- Arvinas price target lowered to $85 from $93 at Stifel
- 04/19/22 UBS
- Roche downgraded to Sell from Neutral at UBS
- 04/14/22 Barclays
- Roche price target raised to CHF 450 from CHF 415 at Barclays
- 01/31/22 Jefferies
- Stoke Therapeutics initiated with a Buy at Jefferies
- 12/03/21
- Fly Intel: Top five analyst initiations
- 12/03/21 BofA
- Stoke Therapeutics initiated with a Buy at BofA
- 12/03/21 BofA
- Stoke Therapeutics initiated with a Buy at BofA
- 01/04/22 Roth Capital
- Unity Biotechnology upgraded to Buy at Roth Capital on 2022 clinical plans
- 01/04/22 Roth Capital
- Unity Biotechnology upgraded to Buy from Neutral at Roth Capital
- 12/15/21 Wedbush
- Wedbush bullish on Unity Biotechnology, initiates with an Outperform
- 12/15/21 Wedbush
- Unity Biotechnology assumed with an Outperform at Wedbush
- 03/15/22
- Unity Biotechnology reports Q4 EPS (18), consensus (38c)
- 11/10/21
- Unity Biotechnology reports Q3 EPS (30c), consensus (37c)
- 03/10/22
- Stoke Therapeutics reports Q4 EPS (66c), consensus (62c)
- 11/08/21
- Stoke Therapeutics reports Q3 EPS (61c), consensus (59c)
- 04/25/22
- Roche reports Q1 group sales CHF 16.445B vs. CHF 14.93B last year
- 02/03/22
- Roche sees FY22 core earnings growing in low- to mid-single digit range
- 02/03/22
- Roche reports 2021 core EPS CHF 19.81 vs CHF 19.16
- 03/01/22
- Regenxbio reports Q4 EPS $6.67, consensus $4.71
- 11/02/21
- Regenxbio reports Q3 EPS ($1.37), consensus ($1.08)
- $658.67 /
-0.225 (-0.03%) - 02/04/22
- Regeneron reports Q4 EPS $23.72, consensus $18.02
- 02/03/22
- Notable companies reporting before tomorrow's open
- 11/04/21
- Regeneron reports Q3 EPS $15.37, consensus $9.56
- 02/24/22
- ProQR Therapeutics reports Q4 EPS (EUR0.26) vs. (EUR0.26) last year
- 11/04/21
- ProQR Therapeutics reports Q3 EPS (EUR0.22) vs. (EUR0.26) last year
LCTX Lineage Cell Therapeutics - 03/10/22
- Lineage Cell Therapeutics reports Q4 EPS (17c), consensus (5c)
- 11/10/21
- Lineage Cell Therapeutics reports Q3 EPS (5c), consensus (5c)
- 03/01/22
- Kodiak Sciences reports Q4 EPS ($1.79), consensus ($1.36)
- 11/09/21
- Kodiak Sciences reports Q3 EPS ($1.30), consensus ($1.16)
KALA Kala Pharmaceuticals - 03/29/22
- Kala Pharmaceuticals reports Q4 EPS (68c), consensus (41c)
- 11/15/21
- Kala Pharmaceuticals reports Q3 EPS (43c), consensus (43c)
- $180.45 /
-0.185 (-0.10%) - 04/19/22
- Johnson & Johnson cuts FY22 adj. EPS view to $10.15-$10.35 from $10.40-$10.60
- 04/19/22
- Johnson & Johnson reports Q1 adjusted EPS $2.67, consensus $2.61
- 04/18/22
- Notable companies reporting before tomorrow's open
HZNP Horizon Therapeutics - 03/01/22
- Horizon Therapeutics sees FY22 revenue $3.9B-$4B, consensus $3.91B
- 03/01/22
- Horizon Therapeutics reports Q4 EPS $1.41, consensus $1.34
- 11/03/21
- Horizon Therapeutics sees FY21 revenue $3.16B-$3.21B, consensus $3.12B
- 11/03/21
- Horizon Therapeutics reports Q3 EPS $1.75, consensus $1.54
- 02/24/22
- Editas Medicine reports Q4 EPS (61c), consensus (72c)
- 11/08/21
- Editas Medicine reports Q3 EPS (57c), consensus (82c)
- 03/28/22
- Ginkgo Bioworks sees FY22 revenue $325M-$340M, consensus $305.75M
- 03/28/22
- Ginkgo Bioworks reports Q4 EPS ($1.10), consensus (4c)
- 01/12/22
- Ginkgo Bioworks sees 2021 revenue above guidance
- 11/15/21
- Ginkgo Bioworks reports Q3 EPS (8c), two estimates (3c)
- 11/12/21
- Celularity reports Q3 EPS 40c, consensus (34c)
- 04/28/22
- Celanese sees FY22 adjusted EPS approaching FY21 adjusted EPS
- 04/28/22
- Celanese reports Q1 adjusted EPS $5.54, consensus $4.52
- 01/27/22
- Celanese sees FY22 EPS 'at least' $15.00, consensus $15.85
- 01/27/22
- Celanese sees Q1 EPS $4.30-$4.60, consensus $4.19
- 04/27/22
- BioMarin backs FY22 revenue view $2.05B-$2.15B, consensus $2.1B
- 04/27/22
- BioMarin reports Q1 GAAP EPS 63c, consensus 17c
- 02/23/22
- BioMarin sees FY22 revenue $2.05B-$2.15B, consensus $2.14B
- 02/23/22
- BioMarin reports Q4 GAAP EPS (32c), consensus (32c)
- 03/01/22
- Bayer sees 2022 group sales of EUR 47B
- 03/01/22
- Bayer reports Q4 core EPS EUR 1.26 vs. EUR 1.32 last year
- 11/09/21
- Bayer reports Q3 core EPS EUR 1.05 vs. EUR 0.81 last year
- 02/14/22
- Applied Genetic reports Q2 EPS (45c), consensus (38c)
- 11/09/21
- Applied Genetic sees cash, cash equivalents funding operations into 2023
- 11/09/21
- Applied Genetic reports Q1 EPS (40c), consensus (35c)
AERI Aerie Pharmaceuticals - 02/24/22
- Aerie Pharmaceuticals reports Q4 EPS $1.09, consensus (67c)
- 11/04/21
- Aerie Pharmaceuticals reports Q3 adjusted EPS (72c), consensus (62c)
ADVM Adverum Biotechnologies - 03/29/22
- Adverum Biotechnologies reports Q4 EPS (35c), consensus (34c)
- 11/04/21
- Adverum Biotechnologies reports Q3 EPS (39c), consensus (37c)
- 03/31/22
- Abeona Therapeutics reports Q4 EPS (45c), consensus (15c)
- 11/15/21
- Abeona Therapeutics reports Q3 EPS (7c), consensus (16c)
- 04/29/22
- AbbVie sees FY22 revenue $59.4B, consensus $60.22B
- 04/29/22
- AbbVie sees Q2 adjusted EPS $3.38-$3.42, consensus $3.50
- 04/29/22
- AbbVie cuts FY22 adjusted EPS view to $13.92-$14.12 from $14.00-$14.20
- 04/29/22
- AbbVie reports Q1 adjusted EPS $3.16, consensus $3.14
|
|
Syndicate
| ShowHide Related Items >><< - 02/15/22
- FDA grants Celularity fast track designation for CYNK-101
- 02/14/22
- Celularity's treatment of gastric junction cancer gets FDA orphan designation
- 01/18/22
- Celularity receives Fast Track Designation for CYNK-101
- 12/27/21
- Celularity receives Fast Track Designation for CYNK-001
- 04/06/22 Truist
- Celularity downgraded to Hold from Buy at Truist
- 04/01/22 Oppenheimer
- Celularity price target raised to $10 from $9 at Oppenheimer
- 01/27/22 Oppenheimer
- Celularity initiated with an Outperform at Oppenheimer
- 11/24/21 Morgan Stanley
- Celularity initiated with an Equal Weight at Morgan Stanley
- 11/12/21
- Celularity reports Q3 EPS 40c, consensus (34c)
- 01/28/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 04/28/22
- Largest borrow rate increases among liquid names
- 04/22/22
- Largest borrow rate increases among liquid names
- 04/08/22
- Largest borrow rate increases among liquid names
- 03/14/22
- Celularity options imply 26.7% move in share price post-earnings
|
|
Options
|
Latest data shows the… Latest data shows the largest indicative borrow rate increases among liquid option names include: Shift Technologies (SFT) 6.98% +2.64, Spring Valley Acquisition Corp (SV) 8.02% +1.42, New Fortress Energy (NFE) 1.03% +0.78, Meta Materials (MMAT) 10.73% +0.57, (STRY) 18.89% +0.50, Frontline (FRO) 7.63% +0.46, Celularity (CELU) 82.74% +0.36, ProShares Ultra (BOIL) 6.38% +0.25, Clever Leaves (CLVR) 35.94% +0.20, and East Stone Acquisition Corp (ESSC) 6.11% +0.19. ShowHide Related Items >><< SV Spring Valley Acquisition Corp. - 04/26/22
- NuScale Power signs MOU with GS Energy, Doosan, and Samsung
- 04/06/22
- Nucor confirms $15M investment in NuScale Power
- 04/06/22
- NuScale Power, Spring Valley announce $15M PIPE investment from Nucor
- 03/29/22
- NuScale Power, Spring Valley Acquisition Corp. announce additional $10M PIPE
- 04/04/22
- Starry rises 17.1%
- 04/03/22
- Fly Intel: Top five weekend stock stories
- 03/30/22
- Starry falls -14.1%
- 03/29/22
- Starry completes transaction with FirstMark to become publicly traded
- 03/15/22
- Shift acquires Fair's dealer listing marketplace tech, SoftBank provides funding
- 12/13/21
- Shift Technologies announces $100M floorplan facility with Ally Financial
- 11/08/21
- Shift Technologies names Ryan Lawrence as general counsel
- 11/04/21
- Shift Technologies names George Arison as sole CEO, effective Feb. 1, 2022
- 04/26/22
- New Fortress Energy application for LNG solution in U.S. GOM advances
- 04/06/22
- Golar LNG sells New Fortress Energy shares for proceeds of $250M
- 03/31/22
- New Fortress Energy files application to deploy fast LNG solution in U.S. GOM
- 03/16/22
- New Fortress Energy signs LNG Sale and Purchase Agreement with Venture Global
- 04/27/22
- Meta Materials appoints George Francis as CIO
- 04/06/22
- Meta Materials announces expanded organizational structure
- 04/05/22
- Meta Materials receives $2.2M additional central bank purchase orders
- 04/04/22
- Meta Materials acquires Plasma App in $20M stock for stock transaction
ESSC East Stone Acquisition - 01/18/22
- East Stone Acquisition Corp trading resumes
- 01/18/22
- East Stone Acquisition Corp trading halted, volatility trading pause
- 12/13/21
- East Stone Acquisition Corp trading resumes
- 12/13/21
- East Stone Acquisition Corp trading halted, volatility trading pause
- 04/27/22
- Clever Leaves Germany becomes fully licensed medical cannabis distributor
- 04/20/22
- Clever Leaves enters partnership with Biom Therapeutics
- 04/04/22
- Clever Leaves ready to export dried flower from Colombia
- 03/22/22
- InterCure, Clever Leaves enter international strategic partnership
- 02/15/22
- FDA grants Celularity fast track designation for CYNK-101
- 02/14/22
- Celularity's treatment of gastric junction cancer gets FDA orphan designation
- 01/18/22
- Celularity receives Fast Track Designation for CYNK-101
- 12/27/21
- Celularity receives Fast Track Designation for CYNK-001
- 04/28/22 William Blair
- William Blair downgrades Vroom on 'very rough start' to Q2
- 03/30/22 Piper Sandler
- Shift Technologies price target lowered to $10 from $17 at Piper Sandler
- 03/16/22 Northland
- Shift Technologies price target lowered to $6 from $12 at Northland
- 03/16/22 DA Davidson
- Shift Technologies price target lowered to $3 from $7 at DA Davidson
SV Spring Valley Acquisition Corp. - 06/15/21 Lake Street
- Spring Valley Acquisition Corp. initiated with a Buy at Lake Street
- 04/07/22 Credit Suisse
- New Fortress Energy price target raised to $49 from $40 at Credit Suisse
- 04/04/22 Stifel
- New Fortress Energy price target raised to $68 from $45 at Stifel
- 01/20/22 Barclays
- New Fortress Energy price target lowered to $29 from $32 at Barclays
- 11/04/21 JMP Securities
- New Fortress Energy price target lowered to $56 from $69 at JMP Securities
- 04/25/22 Goldman Sachs
- Starry initiated with a Buy at Goldman Sachs
- 04/27/22 Jefferies
- Frontline reinstated with a Hold at Jefferies
- 04/27/22 Jefferies
- Euronav NV downgraded to Hold at Jefferies after merger announcement
- 04/08/22 H.C. Wainwright
- Frontline price target raised to $9 from $8 at H.C. Wainwright
- 06/30/21 Danske Bank
- Frontline upgraded to Buy from Hold at Danske Bank
- 04/06/22 Truist
- Celularity downgraded to Hold from Buy at Truist
- 04/01/22 Oppenheimer
- Celularity price target raised to $10 from $9 at Oppenheimer
- 01/27/22 Oppenheimer
- Celularity initiated with an Outperform at Oppenheimer
- 11/24/21 Morgan Stanley
- Celularity initiated with an Equal Weight at Morgan Stanley
- 03/28/22 Cowen
- Clever Leaves price target lowered to $4 from $6 at Cowen
- 02/10/22 Canaccord
- Clever Leaves price target lowered to $7 from $10 at Canaccord
- 12/23/21 Canaccord
- Clever Leaves price target lowered to $10 from $12 at Canaccord
- 11/12/21 Cowen
- Clever Leaves price target lowered to $6 from $11 at Cowen
ESSC East Stone Acquisition - 03/15/22
- Shift Technologies sees FY22 revenue $1B to $1.1B, consensus $1.04B
- 03/15/22
- Shift Technologies sees Q1 revenue $205M-$215M, consensus $191.51M
- 03/15/22
- Shift Technologies reports Q EPS (70c), consensus (61c)
- 11/11/21
- Shift Technologies sees FY21 revenue $621M-$629M, consensus $594.1M
- 03/01/22
- New Fortress Energy reports Q4 EPS 72c vs. (5c) a year ago
- 11/03/21
- New Fortress Energy reports Q3 EPS (5c) vs. (3c) last quarter
- 02/17/22
- Frontline reports Q4 adjusted EPS (2c) vs. (18c) last quarter
- 11/29/21
- Frontline reports Q3 adjusted EPS (18c) vs. (12c) last quarter
- 03/24/22
- Clever Leaves reports Q4 EPS (91c) vs. (34c) last year
- 02/09/22
- Clever Leaves sees 2022 revenue $20M-$25M, consensus $25.01M
- 02/09/22
- Clever Leaves sees 2021 revenue $15.4M, consensus $15.12M
- 02/09/22
- Clever Leaves sees Q4 revenue $4.2M, consensus $3.93M
- 11/12/21
- Celularity reports Q3 EPS 40c, consensus (34c)
|
